Herbalife Ltd. (HLF) stock analysis
Close on Nov 13, 2026Market cap $1.67BP/E 9.5Yield –
StockData Score
Prices as of Nov 13, 2026How the score works
Mixed10 of 30 checks passed
Herbalife passes 10 of the 30 checks behind our score; 9 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 4/6
- Growth
- 2/6
- Past performance
- 2/6
- Financial health
- 2/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 46.7% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $15.96 is below our fair value estimate of $29.95.
Return on capital over 10%
Return on invested capital was 33.3%, above the 10% that usually covers the cost of capital.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 20.5% of total debt.
What to watch
Earnings shrank over 5 years
Net income shrank 9.3% a year on average over the last five fiscal years.
Revenue growing under 10% a year
Revenue grew -1.1% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -12.0% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -44.0% over the last twelve months, against a 5-year average of -9.3% a year.
Valuation4/6
P/E above its 5-year median
Herbalife's P/E of 9.5 is above its own 5-year median of 6.3.
P/E below the industry
Herbalife's P/E of 9.5 is below the Wholesale Trade-non-durable Goods median of 22.6.
EV/EBITDA below its 5-year median
Herbalife's EV/EBITDA of 5.1 is below its 5-year median of 5.8.
P/S above the industry
Herbalife's price-to-sales of 0.32 is above the Wholesale Trade-non-durable Goods median of 0.30 (book value is negative, so we use sales).
Trading below fair value
The share price of $15.96 is below our fair value estimate of $29.95.
Margin of safety over 20%
The price is 46.7% below fair value, more than the 20% cushion we look for.
Growth2/6
Revenue growing under 10% a year
Revenue grew -1.1% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -12.0% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -44.0% over the last twelve months, against a 5-year average of -9.3% a year.
Growing faster than the industry
Revenue grew 6.4% over the last twelve months; the Wholesale Trade-non-durable Goods median is -5.1%.
Guidance raised
Herbalife raised its FY 2026 Depreciation and amortization, and amortization of SaaS implementation costs outlook on Nov 2, 2026.
Gross margin slipping
Gross margin was 77.6% over the last twelve months, against 78.0% a year earlier.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 33.3%, above the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings shrank over 5 years
Net income shrank 9.3% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 3.4% over the last twelve months, against a 5-year average of 5.3%.
Net margin above the industry
Herbalife's net margin of 3.4% is above the Wholesale Trade-non-durable Goods median of -13.1%.
Financial health2/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 20.5% of total debt.
Interest not well covered
Operating income covers interest expense 2.9 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 1.19 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.56; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Herbalife has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$29.95
The share price is 47% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 14.4× | 6.3× | 22.6× | $24.19 | 44% |
| EV/EBITDA | 8.8× | 5.8× | 11.8× | $38.16 | 39% |
| Earnings power | 8.0% cost of equity | – | – | $26.17 | 17% |
| Fair value | $29.95 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 6.3
- Wholesale Trade-non-durable Goods median 22.6
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $22.49M
- Value traded per 1% price move
- $10.21M
Downside
High risk
- Typical loss in a bad month
- 27.1%
- Volatility (annualized)
- 59%
- Sharpe ratio, 1 year
- 1.12
- Beta to the S&P 500 (5Y)
- 0.59
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.9% | -1.1% | -1.9% | +1.2% | |
| Gross profit | +0.9% | -0.9% | -2.2% | +0.8% | |
| Operating income | +24.6% | -4.1% | -5.6% | -1.9% | |
| Net income | -10.2% | -10.8% | -9.3% | -3.9% | |
| EPS, diluted | -12.0% | -12.0% | -4.5% | +1.0% | |
| Free cash flow | +54.8% | +8.8% | -13.3% | -7.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 364.1% | -59.8% | -34.7% | |
| Return on assets | 10.3% | 12.9% | 8.3% | |
| Current ratio | 1.85 | 1.58 | 1.13 | |
| Debt to equity | 7.38 | -2.84 | -3.87 | |
| Net debt to EBITDA | 1.06× | 1.86× | 2.72× | |
| Interest coverage | 4.6× | 4.8× | 2.2× | |
| Inventory turnover | 2.4× | 2.5× | 2.3× | |
| Capex to revenue | 3.2% | 2.0% | 1.6% | |
| Diluted shares | 172M | 135M | 104M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Herbalife generated $1.79B from operations and spent $1.83B on capital expenditure, dividends and share buybacks. 35% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.5% | 1.83× | -4.19× | -34.7% |
| FY2024 | 5.1% | 1.80× | -2.97× | -27.3% |
| FY2023 | 2.8% | 1.83× | -2.38× | -12.2% |
| FY2022 | 6.2% | 1.87× | -2.09× | -24.2% |
| FY2021 | 7.7% | 1.97× | -2.62× | -39.8% |
| FY2020 | 6.7% | 1.93× | -4.62× | -59.8% |
| FY2019 | 6.4% | 1.78× | -4.91× | -55.9% |
| FY2018 | 6.1% | 1.72× | -5.37× | -56.1% |
| FY2017 | 4.8% | 1.62× | -39.45× | -309.1% |
| FY2016 | 5.8% | 1.78× | 35.32× | 364.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$228.30M
- Cash generatingOperating cash flow above zero$333.30M
- Return on assets improvedROA up on the prior year9.1% → 8.4%
- Earnings backed by cashOperating cash flow above net income$333.30M vs $228.30M
- Less leverageLong-term debt to assets fell72.5% → 70.8%
- Better liquidityCurrent ratio rose0.93 → 1.13
- No dilutionShare count did not rise102M → 104M
- Gross margin improvedGross margin up on the prior year77.88% → 77.87%
- More efficientAsset turnover rose1.78 → 1.85
See a number that looks wrong?